Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 31 |
| Active Pipeline (Recruiting Now) | 6 (3) |
| Completed vs Stopped Early | 23 / 2 (6.5%) |
| Median Closed Actual Enrollment | 280 participants |
| Physical Hospital Site Disclosure | 8.3% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Explore interactive annual charts and M&A subsidiary rollups in the Galderma R&D Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.